Several gene panel studies have been developed and are being utilized to predict prognosis and guide the decision-making process for chemotherapy in estrogen receptor (ER)-positive, HER2-negative breast cancer.[8] However, the precise significance of individual somatic mutations in this context has not yet been fully elucidated. The gene discussed is ERBB2; the disease is breast carcinoma.